The Device on Shubman Gill’s Forehead: Athlete Data, Technology and Unanswered Questions

The small device attached to Shubman Gill’s forehead during India’s rain-affected first ODI against New Zealand attracted more curiosity than the result. India won by five wickets at Eden Park; that fact is clear. There is no evidence, however, that the device had any connection to the result, Gill’s batting or India’s tactics. The image is therefore less a performance story than an opening into a larger question: how information about an athlete’s body is collected, interpreted and used.

The device is described as a product of Temple, a wellness-technology company associated with Zomato co-founder Deepinder Goyal. According to the account, its BrainFlow sensor uses light to try to detect changes in blood flow to the brain. An adhesive patch called Grips holds it to the forehead. Temple also has a proprietary measure called “Entropy”, which the company describes in relation to the body’s moment-to-moment expenditure of energy or stress. Factors such as sleep, stress, caffeine and meditation can affect the reading.

That description sounds like advanced sports science, but a product explanation and independently verified scientific evidence are different things. There are no published readings for Gill, no specific post-match data and no comparable results from before and after he began using the device. There is therefore no basis for concluding that it improved his fitness, decision-making or batting. What is visible so far is the use of technology, not proof of its effectiveness.

Another point remains unresolved: is Gill using the device by personal choice, as part of a team-monitoring programme or through a commercial relationship? The account does not confirm an official India programme, and Gill has not publicly explained why he wears it. New Zealand fast bowler Kyle Jamieson reportedly asked him about the device. That shows it caught the attention of people on the field; it does not establish the technology’s acceptance or effectiveness.

The important distinction is between measurement and decision. A sensor may capture a bodily signal, but interpreting that signal requires an individual baseline, consistent readings and relevant medical or training context. If “Entropy” varies from person to person, directly comparing one player’s reading with another’s may be misleading. The account also says badminton player P. V. Sindhu uses the device. In comments to NDTV, she cautioned that interpretation varies between individuals. That is a useful reminder of the technology’s limits: a single number cannot, on its own, provide a complete picture of a player’s readiness, fatigue or risk.

I have spent years watching matches and working with sports data. A live indicator can arrive quickly without its cause being immediately clear. While working with live data at Euro 2026, I saw that displaying a number and verifying the tactical explanation behind it are separate steps. Cricket demands the same caution. The result of one rain-affected ODI cannot tell us about Gill’s physical condition; the presence of one wearable cannot establish that India has a comprehensive sports-science programme.

The most plausible cricket role for this technology, for now, is to supplement information about individual preparation and recovery—not to act as a proxy for batting performance. In a crowded international schedule, sleep, travel, stress and training load can all affect a player’s preparation. Consistently collected information may help medical and coaching staff ask better questions, but it must be assessed alongside a player’s own account, conventional physical checks and observations from the field. If one score becomes the decisive instruction for selection, training or rest, uncertainty in the measurement can become an error in decision-making.

The device’s appearance in an international match also raises governance questions. There is no indication that it enables communication; as described, it is a passive health-monitoring sensor. There is consequently no reason to raise a match-integrity allegation. Still, it matters who owns the data—the player, the board or the manufacturer—how long it is retained, who can access it and for what purpose. Physiological information is health-related, and the need for consent and transparency increases when a commercial product is involved. The account does not specify an ICC or BCCI rule, approval or data-management policy. It would be premature to allege a breach, but equally premature to assume that every approval question has been settled.

The commercial angle deserves as much attention as the sporting one. When a well-known cricketer is seen wearing a product, viewers may read it as an endorsement, whether intended or not. In Gill’s case, personal use, team use and paid promotion are all unconfirmed. If those distinctions are left unclear, curiosity can quickly turn into inflated expectations about what the product can do. Sindhu’s reported use suggests interest across sports, but two athletes using a device cannot substitute for independent scientific validation.

The most useful next question is not “Has the device made Gill a better player?” but “What does it measure, how is that information validated, and who controls it?” A public explanation from Gill, a confirmed statement from the team, independent research and a clear data-protection policy would move the story from curiosity towards verifiable sports science. Until then, the device on his forehead is a visible sign of a potentially useful technology—not a certificate of proven performance improvement.